LOS ANGELES (MarketWatch) -- Japanese stocks rose in early Monday trading, with weaker-than-expected trade data pushing the yen lower, which in turn helped some export stocks. The Nikkei Stock Average (JP:NIK) added 1% to 14,704.36, with the broader Topix up 0.8%, also enjoying support from gains Friday in the U.S. After data showing exports grew less than analysts had projected, the dollar (USDJPY) moved back above the 98-yen level, sending some exporters climbing, with a 2.2% rise for Fujitsu Ltd. (JP:6702) (FJTSY) , a 1.2% improvement for Alps Electric Co. (JP:6770) , and a 1% bump for Toyota Motor Corp. (JP:7203) (TM) . Shares of Suzuki Motor Corp. (JP:7269) (SZKMF) added 2.9% after a Nikkei report saying the company would record its highest-ever operating profit for the April-September half. Retailers were also a strong spot Monday, with J. Front Retailing Co. (JP:3086) up 2%, online marketplace Rakuten Inc. (JP:4755) (RKUNF) adding 2.4%, and 7-Eleven operator Seven & I Holdings Co. (JP:3382) (SVNDF) ahead by 1.4%.
Top Sliver Stocks To Watch For 2015: Rockwell Medical Technologies Inc.(RMTI)
Rockwell Medical Technologies, Inc. manufactures, sells, and distributes hemodialysis concentrate solutions and dialysis kits primarily in the United States, Latin America, Asia, and Europe. The company?s hemodialysis product duplicates kidney function in patients with failing kidneys, known as end stage renal disease, an advanced stage of chronic kidney disease; and dialysis solutions are used to maintain life, remove toxins, and replace nutrients in the dialysis patient?s bloodstream. Its products include Renal Pure and CitraPure liquid acid concentrate, Dri-Sate dry acid concentrate and mixing systems, RenalPure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrates; and various ancillary products comprising blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies. The company also has a license to manufacture and sell soluble ferric pyrophosphate (SFP), a Phase III clinical trial p roduct to improve the treatment of dialysis patients with iron deficiency. Rockwell Medical Technologies sells its products to domestic hemodialysis providers through direct sales people and independent sales representation companies, as well as through independent sales agents and distributors internationally. The company was founded in 1995 and is based in Wixom, Michigan.
Advisors' Opinion:- [By Jake L'Ecuyer]
Rockwell Medical (NASDAQ: RMTI) was also down, falling 19.90 percent to $10.80 after Brean Capital initiated the company at a Sell rating and a $4 price target.
- [By John Udovich]
Small cap dialysis stock Rockwell Medical Inc (NASDAQ: RMTI) looks set to decline when the market opens after Brean Capital initiated coverage with a sell rating and a price target of $4.00, meaning it might be time to take a closer look at what is going on with the stock along with�the performance of large cap dialysis stocks DaVita Healthcare Partners (NYSE: DVA)�and Fresenius Medical Care (NYSE: FMS) along with small cap dialysis stocks NxStage Medical, Inc (NASDAQ: NXTM).�
- [By Roberto Pedone]
Rockwell Medical (RMTI) manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the U.S. and internationally. This stock closed up 5.3% to $5.17 in Tuesday's trading session.
Tuesday's Range: $4.89-$5.25
52-Week Range: $3.16-$8.59
Tuesday's Volume: 1.15 million
Three-Month Average Volume: 1.26 millionFrom a technical perspective, RMTI bounced sharply higher here right above some near-term support levels at $4.81 to $4.65 with decent upside volume. This move is quickly pushing shares of RMTI within range of triggering a major breakout trade. That trade will hit if RMTI manages to take out its 200-day moving average at $5.24 and then once it clears more near-term resistance at $5.94 with high volume.
Traders should now look for long-biased trades in RMTI as long as it's trending above some key near-term support levels at $4.81 to $4.65 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.26 million shares. If that breakout triggers soon, then RMTI will set up to re-test or possibly take out its next major overhead resistance levels at $8 to $8.50.
Top 5 Japanese Companies To Buy For 2014: Primero Mining Corp (PPP)
Primero Mining Corp. (Primero) is a precious metals producer with operations in Mexico. The Company is focused on precious metals assets in the Americas through acquiring, exploring, developing and operating mineral resource properties. As of December 31, 2011, Primero had one producing property, the San Dimas Mine, located in Mexico�� San Dimas district, on the border of Durango and Sinaloa states, and one exploration property, Ventanas, located in Durango state, Mexico. The San Dimas Mine consists of three underground gold and silver mining operations at Tayoltita, San Antonio (Central Block) and Santa Rita. In 2011, the San Dimas Mine produced 79,564 ounces of gold and 4.6 million ounces of silver. Primero also holds 28 mining concessions (3,470.4 hectares) at Mala Noche-Ventanas-San Cayetano (the Ventanas Project). Primero has three active, wholly owned subsidiaries include Primero Empresa Minera, S.A. de C.V., Silver Trading (Barbados) Ltd. and Primero Mining Luxembourg s.a r.l. Advisors' Opinion:- [By Dan Caplinger]
Dan also highlights a new agreement with Brazil's Vale (NYSE: VALE ) as an example of a new partner streaming agreement that features a focus on gold. Can Silver Wheaton continue to profit from future agreements with partners such as Barrick Gold (NYSE: ABX ) , Primaro Mining (NYSE: PPP ) , and Hudbay Minerals (NYSE: HBM ) ?
- [By MONEYMORNING]
As well, Primero Mining (NYSE: PPP) bought Brigus Gold Corp (USA)(NYSE: BRD) for $220 million, and Asanko Gold (NYSEMKT: AKG) is acquiring PMI Gold Corporation (TSE: PMV).
Top 5 Japanese Companies To Buy For 2014: AeroCentury Corp (ACY)
AeroCentury Corp., incorporated on February 28, 1997, acquires used regional aircraft and engines for lease to foreign and domestic regional carriers. The Company�� portfolio of leased aircraft assets is managed and administered under the terms of a management agreement with JetFleet Management Corp. (JMC), which is an integrated aircraft management, marketing and financing business and a subsidiary of JetFleet Holding Corp (JHC).
As of March 31, 2013, the Company�� aircraft and aircraft engines, which were on lease or held for lease included Bombardier Dash-8-300, Fokker 100, Bombardier Dash-8-Q400, Fokker 50, General Electric CF34-8E5 engine, Saab 340B, Saab 340B Plus, deHavilland DHC-8-100, deHavilland DHC-6, Tay 650-15 engine, General Electric CT7-9B engine and Saab 340A. As of March 31, 2013, 14 of the Company�� assets, comprised of four Fokker 50 aircraft, three Saab 340B aircraft, four Fokker 100 aircraft, two Tay 650-15 engines and one General Electric CT7-9B engine, were off lease.
Advisors' Opinion:- [By John Udovich]
Yesterday around midday,�Netherlands based aviation leasing stock�AerCap Holdings N.V. (NYSE: AER) began surging on rumors and closed up 11.6%, meaning its probably time to take a closer look at those rumors along with aviation leasing peers like small caps or mid caps�Aircastle Limited (NYSE: AYR), Air Lease Corp (NYSE: AL), Fly Leasing Ltd (NYSE: FLY) and AeroCentury Corp (NYSEMKT: ACY).
Top 5 Japanese Companies To Buy For 2014: CEL-SCI Corp (CVM)
CEL-SCI Corporation (CEL-SCI), incorporated on March 22, 1983, is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1 hospitalized patients and CEL-2000, a rheumatoid arthritis treatment vaccine.
Multikine
CEL-SCI's Multikine, is being developed for the treatment of cancer. It is a cancer immunotherapy drugs called Combination Immunotherapy because it combines active and passive immunity in one product. It is the only cancer immunotherapy that both kills cancer cells and activates the general immune system to destroy the cancer. Multikine target the tumor micro-metastases for treatment failure. Multikine is also applicable in many other solid tumors.
New Manufacturing Facility
CEL-SCI's facility manufactures Multikine for CEL-SCI's Phase III clinical trial. CEL-SCI offers the use of the facility as a service to pharmaceutical companies and others, particularly those that need to fill and finish their drugs in a cold environment. Fill and finish is the process of filling injectable drugs in a sterile manner.
LEAPS
CEL-SCI's patented T-cell Modulation Process uses heteroconjugates to direct the body to choose a specific immune response. The heteroconjugate technology, referred to as LEAPS, is intended to stimulate the human immune system to fight bacterial, viral and parasitic infections, as well as autoimmune, allergies, transplantation rejection and cancer. Administered like vaccines, LEAPS combines T-cell binding ligands with small, disease associated and peptide antigens.
Using the LEAPS technology, CEL-SCI has created a peptide treatment for H1N1 (swine flu) hospitalized patients. This LEAPS flu treatment is designed to focus on the conserved, non-changing epitopes of the di! fferent strains of Type A Influenza viruses, including swine, avian or bird, and Spanish Influenza. CEL-SCI's LEAPS flu treatment contains epitopes.
Advisors' Opinion:- [By Bryan Murphy]
Names like Amgen, Inc. (NASDAQ:AMGN) and CEL-SCI Corporation (NYSEMKT:CVM) may have pioneered and even mainstreamed the idea of cancer immunology, but the nature of the branch of biotechnology means any company could send CEL-SCI or Amgen back-pedaling. See, it's not about size or deep pockets in the world of biotech anymore. It's about know-how and an idea, which can just as easily be discovered and developed by a small company as they can be a large company. That's why AMGN and CVM at least need to keep a close eye on budding immunology competitor TNI Biotech Inc. (OTCMKTS:TNIB).
- [By Bryan Murphy]
It may not have blazed a trail into the young, immunology segment of the biotech industry the way Dendreon Corporation (NASDAQ:DNDN) did back in 2010 with the debut of Provenge. It may not have the same immunology pipeline (and company size) that ImmunoGen, Inc. (NASDAQ:IMGN) boasts. One thing is pretty certain about cancer-immunotherapy developer CEL-SCI Corporation (NYSEMKT:CVM) right now, however - its stock may be poised to dole out a much bigger foreseeable-future reward than DNDN or IMGN are.
- [By James E. Brumley]
Little TNI Biotech Inc. (OTCMKTS:TNIB) just gave bigger immunology players like Amgen, Inc. (NASDAQ:AMGN) or CEL-SCI Corporation (NYSEMKT:CVM) a new reason to worry. Though CVM and AMGN aren't exactly sweating bullets yet, TNIB has taken not a big step forward in terms biotechnological progress, but rather, has widened its net with a lateral expansion.
No comments:
Post a Comment